Hoffmann-la Roche Inc.

Engmab Sarl

Roche Glycart Ag

Bristol-myers Squibb Compnay

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Beta Holdings LLC

Tanja Fauti

Christian Klein

Ekkehard Moessner

Pablo Umana

Ralf Hosse

Marina Bacac

Anne Freimoser-Grundschober

Oliver Ast

Klaus Strein

Samuel Moser

Minh Diem Vu

Stefan Klostermann

Wolfgang Schaefer

Joerg Thomas Regula

Pablo Umaña

Michael Molhoj

Christiane Neumann

Christiane Jaeger

Peter Bruenker

Lydia Jasmin Hanisch

Ramona Murr

Sabine Jung-Imhof

Guy Georges

Georg Fertig

Thomas U Hofer

Sabine Imhof-Jung

Claudio Sustmann

Tina Weinzierl

Johannes Auer

Alexander Bujotzek

Johannes Sam

Jenny Tosca Thom

Estelle Marrer-Berger

Stephan Gasser

Jean-Baptiste Vallier

Alejandro Carpy Gutierrez Cirlos

Simon Patrick Keiser

Thomas Hofer

Anneliese Schneider

Maud Lea Mayoux

Thomas Kraft

Helene Cecile Haegel

Stefan Lorenz

Jean-Baptiste Pierre Vallier

Anne Freimoser-grundschober

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/MAGE-A4

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use

The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Tumor-targeted agonistic CD28 antigen binding molecules

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Method for the selection of antibodies against BCMA

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Fc-free antibodies comprising two fab-fragments and methods of use

A bispecific antibody specifically binding to the two targets human CD3&#x3b5; and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Bispecific antibodies against CD3 and BCMA

Growing community of inventors

Zurich, Switzerland

Tanja Fauti